IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 10GRADE F
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
-108.3%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Q32 Bio Inc. (QTTB) receives a "Hold" rating with a composite score of 43.0/100, ranked #594 out of 4446 stocks. Key factor scores: Quality 10/100, Value 79/100, Momentum 76/100. This is quantitative analysis only — not investment advice.
Q32 Bio Inc. (QTTB) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Q32 Bio Inc. Do?
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. Q32 Bio Inc. (QTTB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jodie Pope Morrison and employs approximately 39 people. With a market capitalization of $89M, QTTB is one of the notable companies in the Healthcare sector.
Q32 Bio Inc. (QTTB) Stock Rating — Hold (April 2026)
As of April 2026, Q32 Bio Inc. receives a Hold rating with a composite score of 43.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.QTTB ranks #594 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Q32 Bio Inc. ranks #31 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
QTTB Stock Price and 52-Week Range
Q32 Bio Inc. (QTTB) currently trades at $5.21. The stock gained $0.29 (5.9%) in the most recent trading session. The 52-week high for QTTB is $7.80, which means the stock is currently trading -33.2% from its annual peak. The 52-week low is $1.34, putting the stock 287.4% above its annual trough. Recent trading volume was 252K shares, suggesting relatively thin trading activity.
Is QTTB Overvalued or Undervalued? — Valuation Analysis
Q32 Bio Inc. (QTTB) carries a value factor score of 79/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 2.03x, compared to the Healthcare sector average of 23.63x — a discount of 91%. The price-to-book ratio stands at 2.05x, versus the sector average of 2.75x. The price-to-sales ratio is 0.40x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, QTTB trades at 1.28x EV/EBITDA, versus 6.34x for the sector.
Based on these multiples, Q32 Bio Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
Q32 Bio Inc. Profitability — ROE, Margins, and Quality Score
Q32 Bio Inc. (QTTB) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -108.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -73.7% versus the sector average of -33.1%.
The operating margin is 31.4% (sector: -66.1%). Net profit margin stands at 55.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
QTTB Debt, Balance Sheet, and Financial Health
Q32 Bio Inc. has a debt-to-equity ratio of 47.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.85x, indicating strong short-term liquidity. Total debt on the balance sheet is $11M. Cash and equivalents stand at $49M.
QTTB has a beta of 0.99, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Q32 Bio Inc. is 23/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Q32 Bio Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Q32 Bio Inc. reported revenue of $-875,000 and earnings per share (EPS) of $2.42. Net income for the quarter was $-46M. Operating income came in at $-48M.
In FY 2025, Q32 Bio Inc. reported revenue of $54M and earnings per share (EPS) of $2.42. Net income for the quarter was $30M. Operating income came in at $17M.
In Q3 2025, Q32 Bio Inc. reported revenue of $-220,000 and earnings per share (EPS) of $-0.60. Net income for the quarter was $-7M. Operating income came in at $-8M.
In Q2 2025, Q32 Bio Inc. reported revenue of $-284,000 and earnings per share (EPS) of $-0.78. Net income for the quarter was $-9M. Operating income came in at $-9M.
Over the past 8 quarters, Q32 Bio Inc. has experienced revenue contraction from $0 to $-875,000. Investors analyzing QTTB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
QTTB Dividend Yield and Income Analysis
Q32 Bio Inc. (QTTB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
QTTB Momentum and Technical Analysis Profile
Q32 Bio Inc. (QTTB) has a momentum factor score of 76/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.
QTTB vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing QTTB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full QTTB vs S&P 500 (SPY) comparison to assess how Q32 Bio Inc. stacks up against the broader market across all factor dimensions.
QTTB Next Earnings Date
No upcoming earnings date has been announced for Q32 Bio Inc. (QTTB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy QTTB? — Investment Thesis Summary
Q32 Bio Inc. presents a balanced picture with arguments on both sides. The quality score of 10/100 flags below-average profitability. The value score of 79/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 76/100, suggesting the trend favors buyers. High volatility (stability score 23/100) increases portfolio risk.
In summary, Q32 Bio Inc. (QTTB) earns a Hold rating with a composite score of 43.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on QTTB stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
Q32 Bio Inc. (QTTB) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Q32 Bio Inc. (QTTB) receives a Hold rating, driven by a mixed assessment of its financial performance and future prospects. While the company exhibits compelling value metrics and positive momentum, concerns regarding profitability, investment efficiency, and stability temper our enthusiasm. The critical takeaway is that Q32 Bio's success hinges on the clinical trial outcomes of its lead drug candidates and its ability to manage cash burn effectively.
The company's current valuation appears attractive based on P/E and EV/EBITDA ratios, significantly lower than the healthcare sector average. However, this is juxtaposed against negative free cash flow and a volatile operating history. The Hold rating reflects the uncertainty surrounding the company's ability to translate its pipeline into sustainable profitability, balancing the potential upside with the inherent risks of clinical-stage biotechnology companies.
Business Strategy & Overview
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics for autoimmune and inflammatory diseases. Its strategy revolves around restoring healthy immune balance by targeting specific components of the immune system. The lead product candidate, ADX-097, aims to restore complement regulation and is being developed for renal and other complement-mediated diseases. The second key asset, Bempikibart (ADX-914), targets interleukin-7 receptor alpha to re-regulate adaptive immune function, with ongoing Phase II trials for atopic dermatitis and alopecia areata.
The company's approach involves developing humanized or fully human monoclonal antibodies to modulate immune responses. This strategy aligns with the broader trend in the biotechnology industry towards targeted therapies with improved efficacy and safety profiles. Q32 Bio's focus on autoimmune and inflammatory diseases addresses a significant unmet medical need, offering potential for substantial market opportunities if the clinical trials are successful.
Q32 Bio's revenue stream is currently reliant on collaboration agreements and milestone payments, as evidenced by the significant revenue reported in FY2025. The absence of product revenue underscores the company's pre-commercial stage. The company's strategic positioning involves partnering with larger pharmaceutical companies for late-stage development and commercialization, a common practice among smaller biotech firms to mitigate risk and leverage established infrastructure.
The success of Q32 Bio's business strategy is contingent on several factors, including the successful completion of clinical trials, regulatory approvals, and the ability to secure partnerships for commercialization. The company faces intense competition from other biotechnology and pharmaceutical companies developing therapies for autoimmune and inflammatory diseases. Furthermore, the inherent risks associated with drug development, such as clinical trial failures and regulatory hurdles, pose significant challenges to Q32 Bio's long-term prospects.
Execution Benchmarks audit
Operating Margin
Operating efficiency
31.4%
Sector: -66.1%
-148% VS SCTR
Economic Moat Analysis
Q32 Bio's economic moat is currently assessed as None. As a clinical-stage biotechnology company, it lacks the established revenue streams and market dominance typically associated with a strong moat. The company's competitive advantage, if any, resides in its intellectual property and the potential for its drug candidates to address unmet medical needs in specific autoimmune and inflammatory diseases.
The company's intellectual property, primarily patents covering its drug candidates and related technologies, provides a degree of protection against direct competition. However, the strength of this protection is uncertain, as patents can be challenged or circumvented. Furthermore, the biotechnology industry is characterized by rapid innovation, and new therapies may emerge that render Q32 Bio's products obsolete.
Q32 Bio does not benefit from significant network effects or switching costs. Patients typically have multiple treatment options for autoimmune and inflammatory diseases, and switching between therapies is relatively common. The company's products, if approved, would need to demonstrate superior efficacy and safety to gain market share and establish a competitive advantage.
While Q32 Bio's focus on specific autoimmune and inflammatory diseases may allow it to develop specialized expertise and relationships with key opinion leaders, this is unlikely to translate into a sustainable competitive advantage. Larger pharmaceutical companies with greater resources and established commercial infrastructure are better positioned to compete in these markets.
The potential for Q32 Bio to develop a moat in the future depends on the success of its clinical trials and its ability to secure regulatory approvals and commercialize its products. If its drug candidates demonstrate significant clinical benefits and gain market acceptance, the company may be able to establish a narrow moat based on intellectual property and brand recognition. However, this remains highly uncertain at this stage.
Financial Health & Profitability
Q32 Bio's financial health presents a mixed picture. The company's revenue of $53.74 million and net income of $29.82 million in FY2025 are notable, but a closer examination reveals that these figures are likely driven by collaboration agreements and milestone payments rather than recurring product sales. The negative free cash flow of $-7.23 million indicates that the company is currently burning cash to fund its operations.
The company's balance sheet appears relatively strong, with total cash of $49.04 million and total debt of $11.23 million. The current ratio of 4.85 suggests that Q32 Bio has ample liquidity to meet its short-term obligations. However, the company's cash burn rate raises concerns about its long-term financial sustainability. Without recurring revenue from product sales, Q32 Bio will need to raise additional capital to fund its clinical trials and operations.
Comparing Q32 Bio's profitability metrics to the healthcare sector average reveals significant disparities. While the company's operating margin of 31.5% and net margin of 55.5% are significantly higher than the sector averages of -65.2% and -54.1%, respectively, these figures are likely distorted by the non-recurring revenue events in FY2025. The company's negative ROE of -108.3% underscores its lack of profitability on an ongoing basis.
The quarterly financial history reveals a volatile revenue stream and consistent net losses. The significant revenue reported in FY2025 contrasts sharply with the lack of revenue in FY2024 and the relatively small revenue in FY2023. The company's operating margin has fluctuated wildly, reflecting the impact of milestone payments and research and development expenses. The consistent negative EPS indicates that Q32 Bio is not generating sustainable profits.
Overall, Q32 Bio's financial health is precarious. While the company has a strong balance sheet and ample liquidity, its negative free cash flow and reliance on non-recurring revenue events raise concerns about its long-term financial sustainability. The company will need to demonstrate progress in its clinical trials and secure additional funding to maintain its operations.
Valuation Assessment
Q32 Bio's valuation is complex, presenting both attractive and concerning elements. The company's P/E ratio of 2.8x and EV/EBITDA ratio of 1.5x are significantly lower than the healthcare sector averages of 24.3x and 6.4x, respectively. This suggests that the stock is undervalued relative to its earnings and cash flow. However, these metrics are based on the company's FY2025 results, which were likely inflated by non-recurring revenue events. Therefore, relying solely on these ratios may be misleading.
The company's negative free cash flow complicates the valuation assessment. A traditional discounted cash flow (DCF) analysis is difficult to perform without reliable estimates of future cash flows. Furthermore, the company's high growth potential and inherent risks make it challenging to project future cash flows with any degree of certainty.
Given the company's pre-commercial stage and reliance on clinical trial outcomes, a more appropriate valuation approach may involve using a probability-weighted net present value (NPV) analysis. This approach would involve estimating the potential revenue and expenses associated with each of the company's drug candidates, assigning probabilities of success to each clinical trial, and discounting the resulting cash flows to arrive at a present value.
However, even with a probability-weighted NPV analysis, the valuation remains highly sensitive to the assumptions used. Small changes in the probabilities of success or the discount rate can have a significant impact on the estimated value. Furthermore, the analysis does not account for the potential for future dilution or the impact of competition.
Overall, Q32 Bio's valuation is uncertain. While the company's low P/E and EV/EBITDA ratios may appear attractive, these metrics are based on potentially unsustainable earnings. A more rigorous valuation approach would involve a probability-weighted NPV analysis, but this approach is highly sensitive to the assumptions used. Given the company's inherent risks and uncertainties, a Hold rating is warranted.
Risk & Uncertainty
Q32 Bio faces several significant risks and uncertainties that could negatively impact its business and financial performance. The most prominent risk is the inherent uncertainty associated with clinical trials. The company's drug candidates may fail to demonstrate efficacy or safety in clinical trials, which would result in significant financial losses and a decline in the company's stock price. Clinical trial results are inherently unpredictable, and even promising preclinical data may not translate into successful clinical outcomes.
Another significant risk is the regulatory approval process. Even if the company's drug candidates demonstrate efficacy and safety in clinical trials, they may not receive regulatory approval from the FDA or other regulatory agencies. The regulatory approval process is complex and time-consuming, and there is no guarantee that the company's products will be approved. Delays in regulatory approval could also negatively impact the company's financial performance.
Competition is another significant risk. The biotechnology industry is highly competitive, and Q32 Bio faces competition from other companies developing therapies for autoimmune and inflammatory diseases. Larger pharmaceutical companies with greater resources and established commercial infrastructure may be able to develop and commercialize competing products more effectively. The emergence of new therapies or technologies could also render Q32 Bio's products obsolete.
The company's reliance on collaboration agreements and milestone payments also poses a risk. If the company is unable to secure or maintain these agreements, its revenue and financial performance could be negatively impacted. Furthermore, the terms of these agreements may not be favorable to the company, which could limit its potential upside.
Finally, Q32 Bio's cash burn rate and reliance on external funding pose a financial risk. The company will need to raise additional capital to fund its clinical trials and operations. If the company is unable to secure additional funding on favorable terms, it may be forced to curtail its operations or seek a strategic alternative.
Bulls Say / Bears Say
The Bull Case
BULL VIEWQ32 Bio's ADX-097 and Bempikibart have the potential to address significant unmet needs in autoimmune and inflammatory diseases, leading to substantial market opportunities upon successful clinical trials and regulatory approvals.
BULL VIEWThe company's strong balance sheet, with ample cash and a low debt-to-equity ratio, provides a solid foundation for funding ongoing clinical trials and pursuing strategic partnerships.
BULL VIEWQ32 Bio's significantly lower P/E and EV/EBITDA ratios compared to the healthcare sector suggest the stock is undervalued, offering substantial upside potential as clinical programs advance.
The Bear Case
BEAR VIEWQ32 Bio's negative free cash flow and reliance on milestone payments raise concerns about its long-term financial sustainability, requiring continuous capital raises and diluting shareholder value.
BEAR VIEWThe high risk of clinical trial failures in the biotechnology industry poses a significant threat to Q32 Bio, potentially rendering its drug candidates worthless and wiping out investor capital.
BEAR VIEWThe company's lack of a strong economic moat and intense competition in the autoimmune and inflammatory disease space limit its ability to achieve sustainable profitability and market dominance.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score QTTB and 4,400+ other equities.
Q32 Bio Inc. exhibits a 68% valuation discount relative to institutional benchmarks. This represents a constructive entry window based on current multiples.
Return on Assets
Efficiency of asset utilization
-73.7%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
—
Sector: 71.5%
Operating Margin
Core business profitability
31.4%
Sector: -66.1%
Net Margin
Bottom-line profitability
55.5%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
